NCT04065269 2026-02-20ATARIInstitute of Cancer Research, United KingdomPhase 2 Active not recruiting174 enrolled
NCT03983954 2025-11-28Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.NeoTX Therapeutics Ltd.Phase 1 Active not recruiting120 enrolled
NCT03277482 2025-05-31Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerDana-Farber Cancer InstitutePhase 1 Terminated16 enrolled